Slide 1: We are redefining pregnancy care to reduce the burden of preterm birth
We are redefining pregnancy care to reduce the burden of preterm birth March 2026 ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue
Slide 3: Our Bold Ambition
Our Bold Ambition Our vision is to become a global leader in high-value women’s health diagnostics. We’ll do this by taking a holistic approach to providing pivotal information to providers and patients—simultaneously enabling better health for moms and babies while improving the economics of health
Slide 4: Turning Data Into Better Maternal & Neonatal Outcomes
CORPORATE OVERVIEW Turning Data Into Better Maternal & Neonatal Outcomes THE NEED THE SOLUTION POSITIONED FOR COMMERCIAL INFLECTION ● 1 in 10 babies ● Usher in a new era of ● $95.8M Cash, cash equivalents, and marketable are born too soon1 personalized pregnancy care securities as of December 31, 20
Slide 5: The Need
THE Need ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 6: And identification isn't getting better
THE US HAS A PREMATURE BIRTH PROBLEM And identification isn’t getting better National Vital Statistics Data: Infants were more likely to be admitted to a NICU in 2023 than in 2016, according to the Centers for Disease Control. The percentage of infants admitted rose from 8.7% to 9.8% FROM 2013-20243
Slide 7: Health Cost & Implications
PREMATURE BIRTH LEADS TO Health Cost & Implications 18X+ Extremely Premature Premature Full Term HIGHER BIRTH < 28 weeks < 32 weeks 37-40 weeks COST OF NEWBORNS Risk of death, long NICU stay, respiratory issues, decreased Respiratory issues, significant NICU Lower healthcare condition stay, feeding
Slide 8: How Effective Are Traditional Preterm Birth Screening Methods?
Traditional screening How Effective Are Traditional methods fail to Preterm Birth Screening Methods? identify 81% of women who will actually % of Spontaneous Singleton Preterm Birth Cases Identified 100 experience preterm birth 80 60 81% Only 20% 40 11% OF PREGNANT MOTHERS REPORTED RECEIVING 20 8% I
Slide 9: Product and Science
Science PRODUCT AND ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 10: What is a proteomic test?
THE SCIENCE What is a proteomic test? Measures types & quantities of proteins present in a sample THE PURPOSE Predictive test to detect biomarkers in the blood before symptoms arise WHAT IT MEASURES Risk of developing a condition, and biological effect HOW IT WORKS Uses advanced technologies (mass s
Slide 11: Specific proteins are associated with preterm birth risk
BLOOD-BASED BIOMARKERS IGFBP4 Specific proteins Insulin-like Growth Factor Binding Protein-4 are associated Nutrient Delivery with preterm birth risk Discovered by Sera Prognostics in partnership with 13 Universities SHBG and Medical Institutions Sex Hormone Binding Globulin Signals Inflammation Ref
Slide 12: PreTRM seamlessly integrates into and complements prenatal care workflows
PreTRM SEAMLESSLY INTEGRATES INTO AND COMPLEMENTS PRENATAL CARE WORKFLOWS Blood sample kits are provided for testing during 180/7-206/7 weeks with prepaid shipment to Sera’s lab Sample collection can be performed by staff and aligns with preexisting appointments Results delivered in an average of fi
Slide 13: Test Report
TEST REPORT Communicates a patient’s risk of spontaneous preterm birth & helps physicians engage with patients Final Pregnancies identified as higher risk by the PreTRM Test are at increased risk for*: Spontaneous Longer neonatal preterm birth hospital length of stay Severe adverse neonatal outcomes
Slide 14: Robust Clinical Evidence
Evidence ROBUST CLINICAL ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 15: Sera Drives Strategic Advantage to Deliver Clear Insights
EXCLUSIVE DATA ASSETS Sera Drives Strategic Advantage to Deliver Clear Insights Rich Portfolio Demographic & Advanced Mass of Evidence Geographic Diversity Spectrometry TECHNOLOGY 11+ Published Studies Broad sample collection 300+ proteins analyzed PLATFORM across U.S. population Biobank of Artifici
Slide 16: The Only Clinically Validated Test Available for Early Prediction of Premature Birth
THE PRETRM® TEST The Only Clinically Validated Test Available for Early Prediction of Premature Birth o The PreTRM® Test is highly predictive of spontaneous preterm birth with a single blood draw during 180/7 through 206/7 weeks PAPR of gestation2 Validation o Three Independent Studies (discovery, S
Slide 17: PRIME & AVERT Studies
PRIME & AVERT STUDIES Multiple studies demonstrate an effective approach to managing patients identified as higher risk with the PreTRM® Test AVERT STUDY The Historically Controlled Trial Involved: ChristianaCare Hospital (Newark, DE) Enrolled 1873 patients in the prospective arm compared to 10,000
Slide 18: The PRIME Study Finds PreTRM Test Reduces Earliest Preterm Births
THE PRIME STUDY Finds PreTRM® Test Reduces Earliest Preterm Births & Newborn Complications A pioneering clinical trial assessing the efficacy of the PreTRM Test and preventive interventions in lowering the occurrence of adverse pregnancy outcomes. HIGHER RISK NOT HIGHER RISK NOT HIGHER RISK ©2026 Se
Slide 19: Study Design of PRIME
STUDY DESIGN OF PRIME Neonatal impact of maternal biomarker screening for risk of preterm birth with Enrolled & Randomized 1:1 targeted interventions N=5018 Multicenter, Randomized Controlled Trial Involved: Screened Arm Control Arm 19 U.S. sites, including community practices and N=2526 N=2492 univ
Slide 20: Published in the Society of Maternal Fetal Medicine Journal, PREGNANCY
PRIME: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL Published in the Society of Maternal Fetal Medicine Journal, PREGNANCY Demonstrates Significant Improvements in Neonatal Outcomes With Early Risk Screening With PreTRM® and Targeted Interventions Key findings include: o Recruitment November 2020-Dece
Slide 21: Maternal Focused Strategies Help Increase Gestational Age
EACH DAY MATTERS Maternal Focused Strategies Help Increase Gestational Age Increase in Gestational Age Gestational age amongst the earliest ~10% of births was prolonged by 4.5 days, on average1 Reducing Deliveries Reducing Deliveries Before 32 Weeks Before 35 Weeks 56% reduction in deliveries 32% re
Slide 22: PRIME Demonstrates High Clinical Utility
PRIME DEMONSTRATES HIGH CLINICAL UTILITY Significantly improve neonatal outcomes Fewer health Decrease in complications for NICU newborns Admissions 20% reduction in odds NICU admission of neonatal morbidity1 decreased by 20%1 Cost Savings From PreTRM Screening A NICU day was saved for every 4.2 pat
Slide 23: Consistent Benefit for Multiple Important Outcomes
PRIME STUDY FIGURE 2 Consistent Benefit for Multiple Important Outcomes VARIABLE N RATIO (95% CI) Neonatal morbidity and mortalitya 4756 0.80 (0.66 – 0.96) Neonatal hospital length of stayb 4757 0.95 (0.92 – 0.99) NICU Admissionc 4762 0.78 (0.65 – 0.93) NICU Length of Stayd 4759 1.02 (0.97 – 1.08) 0
Slide 24: Proactive Care Strategies Used for Higher Risk Moms
PROACTIVE CARE STRATEGIES USED FOR HIGHER RISK MOMS Low-Dose Aspirin (81 mg) Taken orally daily until 366/7 Clear direction weeks gestation on managing higher-risk Vaginal Progesterone (200 mg) Administered daily as a 200 mg micronized progesterone suppository pregnancies until 366/7 weeks’ gestatio
Slide 25: Pathway to Commercialization
PATHWAY TO Commercialization PRESENT-105 rev 6.6 ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 26: We Are Entering Commercialization Stage
WITH PRIME PUBLICATION We Are Entering Commercialization Stage ILLUSTRATIVE 2026 PRIME STUDY PUBLISHED Next Phase Research & Clinical Targeted Guideline Broad Market Development Validation & Adoption Inclusion & Adoption Evidence Broad Market Adoption % Follows Key Milestones Generation Payer (Guide
Slide 27: Working to Activate the Ecosystem Within Each State
▪ Ongoing conversations with 2 payers in all targeted states MULTI-STAKEHOLDER ACTIVATION MODEL Working to Activate the Ecosystem State Within Each Medicaid Payer 3 Geography Agency Alternative ▪ Active discussions 1 with potential Partner ▪ Engaged with all tier 1 & partners with 2 states regional
Slide 28: Focusing on 1st and 2nd Wave States Covering ~50% of US Births
TARGETED GEOGRAPHIES STRATEGICALLY Focusing on 1st and 2nd Wave States Covering ~50% of US Births Actively Engaged in 6 States Accounting for 33% of US Births • KOL champions driving strong provider alignment and local advocacy • High Medicaid and maternal care need fueling payer engagement • Establ
Slide 29: Commercialization Strategy in Two Parts
COMMERCIALIZATION STRATEGY IN TWO PARTS PRE-GUIDELINES Targeted Adoption 2026 BECOMING PART OF 2027 Guidelines 2028 SUCCESS FACTORS ❑ Achieving coverage and ❑ Develop local ecosystem reimbursement in target expansion approach with geographies building on roles of field sales, advocacy, ❑ Engagement
Slide 30: From Initial Engagement to State Coverage Decision is ~24+ months
Selected Geographical Real-World Pilots Play Key Role Milestones & Timeline (in months) to Achieve Coverage 0 6 12 18 24+ Alignment on goals and pilot setup Time until 80-90% of claims for delivery submitted Pilot Participant Recruitment Time until all participants deliver Data analysis State Decisi
Slide 31: Reaching Payers with Health Economic Data
REACHING PAYERS WITH Health Economic Data Cumulative Budget Impact Over Time Model based on PRIME abstract CUMULATIVE BUDGET IMPACT ($) MILLIONS 8 outcomes applied to 1M covered lives in a commercial plan to identify savings from PreTRM Testing of moms over time 6 Break-even: Weeks 48-56 (varies bas
Slide 32: Reaching Providers
AWARENESS TO ADOPTION Reaching Providers LINKEDIN CAMPAIGNS 45K MEMBERS OF ACOG TARGETED PUBLIC VIA WEBINAR, NEWSLETTER & RELATIONS PRODUCT THEATRE EARNED MEDIA OMNI 2,300 DEEP ENGAGEMENT CHANNEL APPROACH TARGETS VIA IMPIRICIOUS TEXT 5,000 DOXIMITY DEEP ENGAGEMENTS ©2025 Sera Prognostics, Inc. All r
Slide 33: Reaching Moms with Premature Birth Education
DIGITAL PARTNERSHIP Reaching Moms with Premature Birth Education PreTRM.com 80 % JAN 01 – AUG 04 2025 SESSIONS: 161,309 REACH OF PREGNANT WOMEN 2024 SESSIONS: 72,404 93% REACH OF FIRST 1.1 MILLION MONTHLY TIME MOMS VISITORS WEEK 15 EMAIL 33 PRESENT-105 rev 6.6
Slide 34: 2026 Milestones
{ ON THE HORIZON } 2026 Milestones Guideline Conversations Payer Discussions Medicaid Pilot Expansions Commercialization Driving Next Inflection Points Publications ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademark
Slide 35: Ushers in a new era of personalized pregnancy care
THE PRETRM® TEST Ushers in a new era of personalized pregnancy care ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 36: Leadership Team
THE Leadership Team PRESENT-105 rev 6.6 ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Slide 37: Sera Leadership
Zhenya Lindgardt Sera Leadership President & CEO Former VP of Platform & Customer Engagement, Uber Technologies Former Senior Partner & Managing Director, The Boston Consulting Group Michael Foley, M.D. Tiffany Inglis, M.D. Jay Boniface, Ph.D. Former CEO, The Commons Project Foundation Chief Scienti
Slide 38: Together, We Can Do Better
TOGETHER, WE CAN DO BETTER Educate Providers. Empower Moms. HELP Babies. Advance Science. Elevate Care. Reach Maternity Deserts. Inform Payers. Evoke Change. ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Se